Earnings Releases·Nov 10, 2026, 8:02 AM ET

Co-Diagnostics — Third Quarter 2026 Earnings Summary

Revenue increased to $0.3 million from $0.1 million in Q3 2025, while operating expenses decreased 12% year-over-year to $6.2 million, resulting in an operating loss of $6.3 million compared to $7.0 million in the prior year.
Net loss widened to $6.3 million ($1.01 per share) from $5.9 million ($4.66 per share) in Q3 2025, primarily due to a prior-year income tax benefit, and cash and cash equivalents declined to $0.7 million as of September 30, 2026, from $11.9 million at year-end 2025.
Management announced a senior secured convertible debt financing of approximately $2.1 million completed subsequent to the quarter end, with an additional $1.0 million available subject to conditions.
Strategic progress includes FDA 510(k) and CLIA Waiver submissions for the Co-Dx PCR Flu A/B & RSV test, CDSCO submission for the CoSara PCR MTB test in India, and the first international deployment of Vector Smart equipment to a U.S. Air Force base.
The company appointed Wes Lindsey, Ph.D., MBA, as Chief Scientific Officer to lead FDA engagement, while the Co-Dx PCR platform remains under regulatory review and is not yet available for sale.